The 4th Annual Targeted Radiopharmaceutical Summit 2025
Bioconjugation Insights 2025; 1(3), 71–72
DOI: 10.18609/bci2025.014
As part of our ongoing coverage of key gatherings in the bioconjugation space, Bioconjugation Insights presents an event preview of the 4th Targeted Radiopharmaceuticals Summit 2025. Taking place July 29–31, 2025, in San Diego, the summit will showcase the latest advances, technologies, and collaborative opportunities across the radiopharma pipeline from discovery to commercialization. This preview offers readers a glimpse into the sessions, speakers, and themes that will shape the discussions of this fast evolving therapeutic field.
Novel design approaches
The summit spotlighted innovative strategies in radiopharmaceutical design, with a strong focus on novel targeting molecules and delivery platforms. James Bowman will introduce de novo protein design using AI to create miniproteins with site-specific conjugation handles. Alessandro Mascioni and Guido Wuerth share advances in engineered antibody fragments and Affibody technology for HER2-targeted therapies. Haihong Jin discusses AI-driven medicinal chemistry for peptide-based RLTs. Workshops led by Chris Adams, Keene Wei, Phil Brandish, and Randolf Kerschbaumer explore peptide and mini protein targeting, linker chemistry, and pre-targeting strategies. These sessions collectively emphasized the field’s evolution toward precision-engineered biologics and computational design to enhance efficacy and reduce off-target effects.
Emerging clinical data
Emerging clinical insights are a major theme, with speakers presenting early-phase trial data and translational strategies. Manfred Rudgier and Guido Wuerth share updates on first-in-human studies, while Daniel Stevens highlights the role of dosimetry in early go/no-go decisions. Dylan Stoy presented findings from UCLA’s FLEX and RE-LuPSMA trials, aiming to optimize fixed dosing schedules. Anna Karmann, Alyssa Vito, and Sudhakar Chintharlapalli will discuss Phase 0 strategies to accelerate clinical entry. These sessions underscored the growing importance of early clinical signals, imaging biomarkers, and real-world evidence in refining trial design and guiding regulatory and commercial decisions.
Bioconjugation
Bioconjugation will be explored through sessions on antibody-based radiopharmaceuticals, linker technologies, and radiolabeling strategies. Dirk Pleimes, Xueming Qian, and Randolf Kerschbaumer lead a workshop on antibody conjugates and pre-targeting strategies, addressing challenges in radiolabeling and biological half-life alignment. Chris Adams, Keene Wei, and Phil Brandish discuss linker innovations and chelator design in peptide-based targeting. Haihong Jin presents on AI-driven conjugation chemistry for RLTs. These sessions highlighted how bioconjugation is central to improving pharmacokinetics, targeting specificity, and therapeutic index in next-generation radiopharmaceuticals.
Supply chain
The summit will also cover supply chain innovation, addressing isotope availability, manufacturing scalability, and regulatory integration. Kevin Machel and David Bailey will discuss domestic isotope production and supply chain resilience. Kevin Roland and Shaemus Gleasson explore CMC strategies and regulatory frameworks for scalable production. Ashley Mishoe emphasized harmonizing CDMO and sponsor quality systems. Additional insights come from roundtables and panels featuring Max Smock and Luis Rivera, who address funding trends and logistics. These sessions reinforced the need for robust, decentralized supply chains to support the rapid growth of radiopharmaceutical development and commercialization.
From radiochemistry innovators to clinical trial trailblazers, the 4th Annual Targeted Radiopharmaceuticals Summit US 2025 is your gateway to next-generation conjugation strategies, precision alpha therapies, and scalable isotope supply. Bringing together industry-leading pharma, biotech, and academia, this summit delivers the insights, technologies, and partnerships you need to accelerate clinical translation, streamline manufacturing, and lead the radiopharma revolution in oncology.
As a reader of Bioconjugation Insights, you’re entitled to a 10% discount on delegate tickets—just use the code BCIXTRP! You can find out more about the 4th Annual Targeted Radiopharmaceuticals Summit 2025 events here.
Additionally, to find out what other bioconjugate events are upcoming, you can find our online Events Calendar here.